Page last updated: 2024-11-05

1,3,4-butanetriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3,4-Butanetriol is a trihydric alcohol with the chemical formula HOCH2CH(OH)CH2CH2OH. It is a colorless, viscous liquid that is soluble in water and ethanol. It is a versatile building block for the synthesis of various organic compounds, including pharmaceuticals, polymers, and surfactants. 1,3,4-Butanetriol is also a potential precursor for the production of biodegradable polymers and renewable fuels. It is studied for its potential applications in various fields, including medicine, materials science, and green chemistry. The synthesis of 1,3,4-butanetriol typically involves the reduction of 1,3,4-butanetrione or the hydration of 3-buten-1-ol.'

1,2,4-butanetriol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,2,4-butanetriol : A triol that is butane carrying three hydroxy substituents at position 1, 2 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID18302
CHEMBL ID1356759
CHEBI ID88063
SCHEMBL ID29798
MeSH IDM0295466

Synonyms (59)

Synonym
butane-1,2,4-triol
1,2,4-butanetriol
brn 1733456
nsc 60197
einecs 221-323-5
1,2,4-trihydroxybutane
1,3,4-butanetriol
1,2,4-butantriol [german]
nsc-60197
1,4-trihydroxybutane
1,4-butanetriol
nsc60197
triol 124
2-deoxyerythritol
butane-1,4-triol
3068-00-6
(+/-)-1,2,4-butanetriol, 95%
NCGC00166117-01
NCGC00166126-01
NCGC00166053-01
(+/-)-1,2,4-butanetriol, technical, >=90% (gc)
A637710B-C321-4E3F-A354-64FC18733531
(+/-)-1,2,4-butanetriol
FT-0639811
AKOS000120020
1,2,4-butantriol
unii-nk798c370h
nk798c370h ,
2-01-00-00596 (beilstein handbook reference)
B0687
FT-0605292
FT-0606242
FT-0605119
SCHEMBL29798
1,2,4-butane triol
(+/-)-butane-1,2,4-triol
SY003295
mfcd00002929
CHEMBL1356759
hoch2ch(oh)ch2ch2oh
NCGC00356954-01
tox21_303969
dtxcid6024416
dtxsid8044416 ,
cas-3068-00-6
Q-200057
CHEBI:88063
mfcd00063213
(+/-)-1,2,4-butanetriol, analytical standard
Q4187980
CS-0008443
AS-12262
AC2226
methscopolaminebromide
AMY6061
1.2.4-butanetriol
2,4-trihydroxybutane
SY274042
EN300-20062
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
bacterial xenobiotic metaboliteAny bacterial metabolite produced by metabolism of a xenobiotic compound in bacteria.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triolA chemical compound containing three hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency24.33650.000714.592883.7951AID1259369
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.28180.010039.53711,122.0200AID1479
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency18.53310.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (11.54)18.7374
1990's2 (7.69)18.2507
2000's3 (11.54)29.6817
2010's15 (57.69)24.3611
2020's3 (11.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.17 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]